Ongoing research is focused on understanding resistance mechanisms to IDH inhibitors, as leukemia stemness and co-occurring mutations, such as RUNX1 and RAS-RTK pathway alterations, can drive resistance to these targeted therapies [166]. Here, RUNX1 is linked to leukemia.